A Research Agenda for Malaria Eradication: Drugs

Overview

Journal PLoS Med

Specialty General Medicine

Date 2011 Feb 12

PMID 21311580

Citations 167

Affiliations

Soon will be listed here.

Abstract

Antimalarial drugs will be essential tools at all stages of malaria elimination along the path towards eradication, including the early control or "attack" phase to drive down transmission and the later stages of maintaining interruption of transmission, preventing reintroduction of malaria, and eliminating the last residual foci of infection. Drugs will continue to be used to treat acute malaria illness and prevent complications in vulnerable groups, but better drugs are needed for elimination-specific indications such as mass treatment, curing asymptomatic infections, curing relapsing liver stages, and preventing transmission. The ideal malaria eradication drug is a coformulated drug combination suitable for mass administration that can be administered in a single encounter at infrequent intervals and that results in radical cure of all life cycle stages of all five malaria species infecting humans. Short of this optimal goal, highly desirable drugs might have limitations such as targeting only one or two parasite species, the priorities being Plasmodium falciparum and Plasmodium vivax. The malaria research agenda for eradication should include research aimed at developing such drugs and research to develop situation-specific strategies for using both current and future drugs to interrupt malaria transmission.

Citing Articles

The Advances in Phospholipids-Based Phase Separation Gels for the Sustained Release of Peptides, Proteins, and Chemotherapeutics.

Dong J, Zhou X, Li Q, Zheng R, Chen J, Liu Y Pharmaceutics. 2024; 16(7).

PMID: 39065572 PMC: 11279848. DOI: 10.3390/pharmaceutics16070875.

A dual-antigen malaria vaccine targeting Pb22 and Pbg37 was able to induce robust transmission-blocking activity.

Gao W, Qiu Y, Zhu L, Yu X, Yang F, Chen M Parasit Vectors. 2023; 16(1):455.

PMID: 38098083 PMC: 10720250. DOI: 10.1186/s13071-023-06071-x.

Perceptions and drivers of healthcare provider and drug dispenser practices for the treatment of malaria in pregnancy in the context of multiple first-line therapies in western Kenya: a qualitative study.

Osoro C, Dellicour S, Ochodo E, Young T, Kuile F, Gutman J Malar J. 2023; 22(1):274.

PMID: 37710229 PMC: 10503024. DOI: 10.1186/s12936-023-04698-w.

Biology and epidemiology of and gametocyte carriage: Implication for malaria control and elimination.

Alemayehu A Parasite Epidemiol Control. 2023; 21:e00295.

PMID: 36950502 PMC: 10025134. DOI: 10.1016/j.parepi.2023.e00295.

Epigenetic and Epitranscriptomic Gene Regulation in and How We Can Use It against Malaria.

Serrano-Duran R, Lopez-Farfan D, Gomez-Diaz E Genes (Basel). 2022; 13(10).

PMID: 36292619 PMC: 9601349. DOI: 10.3390/genes13101734.

References

Marsh K . Malaria--a neglected disease?. Parasitology. 1992; 104 Suppl:S53-69. DOI: 10.1017/s0031182000075247. View

Han E, Lee D, Park K, Seok W, Kim Y, Tsuboi T . Reemerging vivax malaria: changing patterns of annual incidence and control programs in the Republic of Korea. Korean J Parasitol. 2006; 44(4):285-94. PMC: 2559126. DOI: 10.3347/kjp.2006.44.4.285. View

. A research agenda for malaria eradication: modeling. PLoS Med. 2011; 8(1):e1000403. PMC: 3026697. DOI: 10.1371/journal.pmed.1000403. View

Price R, Dorsey G, Ashley E, Barnes K, Baird J, DAlessandro U . World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J. 2007; 6:119. PMC: 2008205. DOI: 10.1186/1475-2875-6-119. View

BRUCE-CHWATT L . Malaria research and eradication in the USSR. A review of Soviet achievements in the field of malariology. Bull World Health Organ. 1959; 21:737-72. PMC: 2537933. View

Nyunt M, Hendrix C, Bakshi R, Kumar N, Shapiro T . Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2009; 80(4):528-35. PMC: 2763313. View

Dondorp A, Nosten F, Yi P, Das D, Phyo A, Tarning J . Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361(5):455-67. PMC: 3495232. DOI: 10.1056/NEJMoa0808859. View

Kelly-Hope L, Ranson H, Hemingway J . Lessons from the past: managing insecticide resistance in malaria control and eradication programmes. Lancet Infect Dis. 2008; 8(6):387-9. DOI: 10.1016/S1473-3099(08)70045-8. View

Plowe C, Alonso P, Hoffman S . The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis. 2009; 200(11):1646-9. DOI: 10.1086/646613. View

10.

Price R, Tjitra E, Guerra C, Yeung S, White N, Anstey N . Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2008; 77(6 Suppl):79-87. PMC: 2653940. View

11.

Ruwende C, Khoo S, Snow R, Yates S, Kwiatkowski D, Gupta S . Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature. 1995; 376(6537):246-9. DOI: 10.1038/376246a0. View

12.

Najera J . Malaria control: achievements, problems and strategies. Parassitologia. 2002; 43(1-2):1-89. View

13.

. A research agenda for malaria eradication: monitoring, evaluation, and surveillance. PLoS Med. 2011; 8(1):e1000400. PMC: 3026689. DOI: 10.1371/journal.pmed.1000400. View

14.

von Seidlein L, Greenwood B . Mass administrations of antimalarial drugs. Trends Parasitol. 2003; 19(10):452-60. DOI: 10.1016/j.pt.2003.08.003. View

15.

Chanda P, Hamainza B, Mulenga S, Chalwe V, Msiska C, Chizema-Kawesha E . Early results of integrated malaria control and implications for the management of fever in under-five children at a peripheral health facility: a case study of Chongwe rural health centre in Zambia. Malar J. 2009; 8:49. PMC: 2662870. DOI: 10.1186/1475-2875-8-49. View

16.

. A research agenda for malaria eradication: health systems and operational research. PLoS Med. 2011; 8(1):e1000397. PMC: 3026705. DOI: 10.1371/journal.pmed.1000397. View

17.

Dondorp A, Yeung S, White L, Nguon C, Day N, Socheat D . Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010; 8(4):272-80. DOI: 10.1038/nrmicro2331. View

18.

Alker A, Lim P, Sem R, Shah N, Yi P, Mey Bouth D . Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg. 2007; 76(4):641-7. View

19.

Dola S . Mass drug administration as a supplementary attack measure in malaria eradication programme. East Afr Med J. 1974; 51(7):529-31. View

20.

Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M . Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359(24):2619-20. DOI: 10.1056/NEJMc0805011. View